TNGX - NASDAQ
Tango Therapeutics, Inc.
$21.47
-7.1%Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotTango Therapeutics, Inc. Management Team
Ms. Daniella Beckman CPA
Chief Financial Officer
Compensation
$717,616
Ms. Julie Carretero
Chief Human Resources Officer
Mr. Douglas J. Barry Esq., J.D.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Compensation
$674,222
Mr. Jannik N. Andersen Ph.D.
Chief Scientific Officer
Dr. Antoni Ribas M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. William G. Kaelin Jr., M.D.
Founder & Member of Scientific Advisory Board
Dr. Michael Palmieri Ph.D.
Head of Technical Operations
Dr. Adam S. Crystal M.D., Ph.D.
President of Research & Development
Compensation
$882,167
Dr. Barbara L. Weber M.D.
President, Chief Executive Officer & Director
Compensation
$1,125,489
Ms. Elizabeth Pingpank Hickin
Vice President of IR & Corporate Communications
Tango Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.33M and sold $29.80M worth of TNGX shares, resulting in $28.47M of net selling activity.
3 Months
0
0.00
103.4K
2.32M
-2.3M
-$2.32M
3-6 Months
0
0.00
84.8K
1.12M
-1.1M
-$1.12M
6-9 Months
150.0K
1.20M
1.4M
12.02M
-10.8M
-$10.82M
9-12 Months
37.5K
131.62K
2.0M
14.33M
-14.2M
-$14.20M
Top Buyers
Peters Malte
Director
$1.33M
Top Sellers
Third Rock Ventures Iv, L.P.
10 Percent Owner
$26.35M
Crystal Adam
Officer: President, R&D
$3.32M
Beckman Daniella
Officer: Chief Financial Officer
$125K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $28.47M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
TNGX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | April 16, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2025 | April 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 24, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | June 08, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.